W
Wallaby Medical
Emerging medical device company focused on developing therapies for vascular disease
About Wallaby Medical
Wallaby Medical is a medical device company focused on developing and commercializing technologies for the treatment of strokes. The company was founded in December 2015 by Michael Alper and Bing Liu, who serve as CEO and Chairman, respectively. Michael Alper, originally from New York with a background in computer science, transitioned to the medical device industry after his MBA, working at Medtronic in Asia before starting Wallaby. His experience in the Asian market highlighted the high incidence of stroke among East Asian populations, which became a key motivator for the company's mission.
The company's business is centered on the design, manufacturing, and sale of neurovascular interventional products used to treat both ischemic and hemorrhagic strokes. Its clients are hospitals and medical professionals specializing in neurovascular procedures. Wallaby Medical operates globally, with a strong presence in the United States, China, Europe, and Japan, and its products are sold in over 60 countries. The company's revenue is generated through the sale of its medical devices. A significant milestone was the acquisition of phenox GmbH, a German neurovascular company, in April 2022 for approximately €500 million. This acquisition, which included phenox's sister company femtos GmbH, significantly expanded Wallaby's product portfolio and geographic footprint, combining complementary technologies with no product overlap.
Wallaby Medical's product portfolio includes the Avenir® Coil System, a neuro embolic coil system for treating intracranial aneurysms, which has received FDA, CE Mark, and Japan PMDA approval. The company also offers the Esperance™ Aspiration Catheter for ischemic stroke treatment, which is cleared in the U.S. and China. Through the phenox acquisition, the company's offerings grew to include the pRESET® series of stent retrievers for mechanical thrombectomy and the p64/p48 Flow Modulation Devices for treating intracranial aneurysms, both approved in Europe. The combined entity now boasts a comprehensive product line for stroke care, supported by 5 R&D centers and 3 production bases worldwide.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 32.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Apr 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Mar 2026 | $0 | — | Undisclosed | ↗ |
| LATE VCOther financing | Mar 2026 | $0 | — | Hillhouse Capital · Qianhai Ark Asset Management · Yingmai Medical · Gaorong Capital | ↗ |
Growth signals
Latest recorded traffic for Wallaby Medical is 990 monthly website visits, down 61.9% over the last three months. Wallaby Medical's team declined 10.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Wallaby Medical in the Laguna Hills ecosystem
The Wallaby Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CD Capital
Series A4 investors entered at this stage
CITIC Medical
Qianhai FOF- MCMaison Capital
Chang 'an Capital
Series B and later8 investors entered at this stage
GL Ventures
Hillhouse Capital
Sinovation Ventures- QMQianhai Ark Asset Management
Gaorong Capital
YunFeng Capital
Junson Capital
Yingmai Medical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Wallaby Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Wallaby Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










